This HTML5 document contains 155 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n8http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q30234419
rdf:type
wikibase:Item
schema:description
2017 թվականի մարտին հրատարակված գիտական հոդված wissenschaftlicher Artikel scienca artikolo מאמר מדעי научна статия artigo científico (publicado na 2017) научни чланак 2017年論文 επιστημονικό άρθρο სამეცნიერო სტატია 2017年论文 vědecký článek vedecký článok vetenskaplig artikel 2017年論文 naučni članak 2017年论文 мақолаи илмӣ مقالة علمية (نشرت في 4-3-2017) บทความทางวิทยาศาสตร์ artikull shkencor vitskapeleg artikkel artykuł naukowy tieteellinen artikkeli 2017年の論文 artículo científico publicado en 2017 articol științific 2017年论文 article scientific artigo científico 2017年論文 2017年论文 ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научни чланак سائنسی مضمون article científic 2017 թուականի Մարտին հրատարակուած գիտական յօդուած artigo científico (publicado na 2017) мақолаи илмӣ 2017年论文 bilimsel makale vitenskapelig artikkel artículu científicu espublizáu en 2017 наукова стаття, опублікована в березні 2017 scientific article tudományos cikk 2017 nî lūn-bûn научная статья مقالهٔ علمی 2017年论文 article scientifique (publié 2017) 2017年論文 videnskabelig artikel (udgivet 2017) articolo scientifico 2017년 논문 wetenschappelijk artikel mokslinis straipsnis teaduslik artikkel artikulong pang-agham 2017年論文 bài báo khoa học
p:P577
wds:Q30234419-0189B50B-FDA4-49AB-9C93-4FFCBA8B9631
wdt:P577
2017-03-04T00:00:00Z
p:P2093
wds:Q30234419-D481F131-8628-4796-B7A1-48B8E8DEA63B wds:Q30234419-CEF9BA81-D0E6-4913-934E-EFFA676FDAAF wds:Q30234419-F750A141-B354-400B-AC5C-02E805D6AAB2 wds:Q30234419-F101527B-1394-4C97-A8C8-C5AF0E9192B1 wds:Q30234419-F13B0F50-9C6A-41C0-BEF4-7805F792F041 wds:Q30234419-82977B7E-E064-4D69-B999-7B57EDC9082A wds:Q30234419-755DDC88-5ABD-4976-B5CF-CB82CE55647C wds:Q30234419-78C5FF03-1EA9-4E4C-83E1-0275A144A46D wds:Q30234419-753E61C2-D360-45B0-A8C7-9BFB45C3F644 wds:Q30234419-4DD32B4C-301A-4866-A1C6-069512F812A8 wds:Q30234419-96CE660D-87F3-4537-BE87-91BDD8E6DF2A wds:Q30234419-841CA1FD-BADF-413D-B2DB-E42087289BF9 wds:Q30234419-8B6BA63F-35C9-412F-8B4B-A0F6BEB76BF2 wds:Q30234419-0F46AEB0-0D78-42AF-84C5-4D63CEE80D51 wds:Q30234419-226D4AB9-9225-49C8-96D3-074FBCBCF5D5 wds:Q30234419-4469327F-3910-48D6-81E6-127B0C0A64E2 wds:Q30234419-377DEBA2-7CA9-4CAA-97D3-8875EA504935 wds:Q30234419-3F434CEF-8C2C-42C6-A838-6A720560165F wds:Q30234419-358675E9-B7FB-4A40-8751-4D2301B79ACD wds:Q30234419-23E7928C-4967-4115-B591-6228A7664885 wds:Q30234419-29E098D5-3029-43AD-8F62-658C9F39061C
wdt:P2093
Konstantinos Tziomalos Themistoklis Tzotzas Michael Doumas Niki Katsiki Olga Giouleme John Goudevenos Moses S Elisaf Emmanuel S Ganotakis Asterios Karagiannis Konstantinos Tsioufis Vasilios G Athyros Loukianos S Rallidis Helen Bilianou Georgios Germanidis Vasilios Kotsis Stergios Polyzos Charalambos Karvounis Alexandros D Tselepis Themistoklis G Vasiliadis Evangelos Liberopoulos Dimitrios Richter
rdfs:label
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
skos:prefLabel
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
schema:name
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
p:P50
wds:Q30234419-F2760925-4E6F-4A82-A206-493830CCDDEE wds:Q30234419-D974589E-473A-4995-82DB-B399CCF30218 wds:Q30234419-AA58D9F2-45D3-4667-B247-F5B6A2BFDA05 wds:Q30234419-8C544A81-9D2C-4BDD-B1A9-9BAEC67C9798 wds:Q30234419-9665A9B4-175A-46C1-8094-7D92BFFA79A6 wds:Q30234419-7E4B487F-12B1-4F70-A108-5955BF79077E wds:Q30234419-74DF5184-53F2-41C2-8EAD-54503B55673F wds:Q30234419-46B5A9BF-41D5-4B04-B5FF-0B81619CBA1A
wdt:P50
wd:Q26702668 wd:Q87975498 wd:Q90301782 wd:Q28321351 wd:Q58933953 wd:Q62561943 wd:Q88459731 wd:Q57021359
p:P1476
wds:Q30234419-D4882102-465A-41B4-B03B-34A0A81CFC31
wdt:P1476
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
p:P304
wds:Q30234419-D5E78EE1-4861-4230-90E5-ADE6F804C0DD
wdt:P304
17-32
p:P31
wds:Q30234419-b4c440b4-4656-4355-abb9-b8ae4f371760 wds:Q30234419-9ED97CE9-32F2-4F01-9C3E-DA118359BEA3
wdt:P31
wd:Q7318358 wd:Q13442814
p:P921
wds:Q30234419-2DF31C96-4B8E-4742-A99E-01FAD8F4C935 wds:Q30234419-F066188D-8FDF-459B-8FFF-957ADE5C511D wds:Q30234419-CD83DED4-33C9-4ECD-998D-189BBFFA4FCC
wdt:P921
wd:Q2335423 wd:Q1546498 wd:Q66299798
p:P698
wds:Q30234419-E5EE7774-B216-4959-9EBC-2945524871ED
wdtn:P698
n11:28521870
wdt:P698
28521870
p:P1433
wds:Q30234419-597FD9C2-0D79-4A28-B0F9-38581AC1C7A9
wdt:P1433
wd:Q15764354
p:P478
wds:Q30234419-B10861BD-25E5-43D9-860E-CF490761D989
wdt:P478
71
p:P356
wds:Q30234419-034C7249-79BF-4889-A22E-6783A0772FD3
wdtn:P356
n8:J.METABOL.2017.02.014
wdt:P356
10.1016/J.METABOL.2017.02.014